BCT

BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences

Retrieved on: 
Wednesday, October 18, 2023
Patient, Antibody, Metastatic breast cancer, Annual general meeting, Therapy, Breast cancer, BCT, TSX, Vaccine

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that BriaCell will be presenting at the following two upcoming scientific conferences.

Key Points: 
  • PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that BriaCell will be presenting at the following two upcoming scientific conferences.
  • The 2023 SITC 38th Annual Meeting will be taking place November 3-5, 2023 at San Diego Convention Center, San Diego, CA.
  • The 2023 San Antonio Breast Cancer Symposium® will be taking place December 5-9, 2023 at Henry B. Gonzalez Convention Center, San Antonio, TX.
  • Abstract Title: Analysis of Antibody Response to SV-BR-1-GM Therapeutic Vaccine in Breast Cancer Patients Using Human Protein Microarrays: Potential Correlations with Therapy Response
    Abstract Title: Randomized Phase 2 of Bria-IMT™, an Allogenic Human Cell Line with Antigen Presenting Activity, in Heavily Pretreated Metastatic Breast Cancer

POTOMAC BANCSHARES, INC. DECLARES QUARTERLY DIVIDEND

Retrieved on: 
Thursday, October 19, 2023
OTC, Bank, BCT, The Company, The Hunt for Red October (board game), Holding company, Security (finance)

CHARLES TOWN, W.Va., Oct. 19, 2023 /PRNewswire/ -- The Board of Directors of Potomac Bancshares, Inc. (the "Company") (OTC: PTBS), the one bank holding company for Bank of Charles Town (BCT), declared at their October Board meeting a quarterly dividend of $0.10 per share.

Key Points: 
  • CHARLES TOWN, W.Va., Oct. 19, 2023 /PRNewswire/ -- The Board of Directors of Potomac Bancshares, Inc. (the "Company") (OTC: PTBS), the one bank holding company for Bank of Charles Town (BCT), declared at their October Board meeting a quarterly dividend of $0.10 per share.
  • The dividend is for all shareholders of record on November 2, 2023, and will be paid on November 9, 2023.

BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic

Retrieved on: 
Wednesday, October 11, 2023
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mayo Clinic, TSX, Doctor of Philosophy, Bria, KOL, University, Survival, University of Pittsburgh School of Medicine, Therapy, BCT, FACP, Wilfrid Sellars, Fast Track, Literature, Patient, Pharmaceutical industry, MD

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that it will host a virtual KOL event on Bria-IMT™ potential in advanced metastatic breast cancer on Thursday, October 26, 2023 at 10:00am ET.

Key Points: 
  • PHILADELPHIA and VANCOUVER, British Columbia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that it will host a virtual KOL event on Bria-IMT™ potential in advanced metastatic breast cancer on Thursday, October 26, 2023 at 10:00am ET.
  • To register for the event, please click here .
  • The event will feature KOLs Adam M. Brufsky, MD, PhD, FACP (University of Pittsburgh School of Medicine) and Saranya Chumsri, MD (Mayo Clinic) who will discuss the unmet medical need and current treatment landscape for patients suffering from advanced metastatic breast cancer, along with the combination study of Bria-IMT™ with immune check point inhibitor.
  • The event’s agenda is summarized below:
    BriaCell Virtual KOL Event Agenda – October 26, 2023

Alice Frazier, BCT President and CEO, Honored at Washington Business Journal's 2023 Women Who Mean Business Gala

Retrieved on: 
Friday, October 6, 2023
Community Bank (Oregon), Woman, The Ritz-Carlton Hotel Company, OTC, Washington metropolitan area, Community, American City Business Journals, BCT, Bank

CHARLES TOWN, W.Va., Oct. 6, 2023 /PRNewswire/ -- (OTC:PTBS) BCT-Bank of Charles Town, also known as The Community's Bank, is pleased to announce that Alice Frazier, President and CEO, and member of the Board of Directors, was recognized as one of the select Honorees at the Washington Business Journal's 2023 Women Who Mean Business gala.

Key Points: 
  • CHARLES TOWN, W.Va., Oct. 6, 2023 /PRNewswire/ -- (OTC:PTBS) BCT-Bank of Charles Town, also known as The Community's Bank, is pleased to announce that Alice Frazier, President and CEO, and member of the Board of Directors, was recognized as one of the select Honorees at the Washington Business Journal's 2023 Women Who Mean Business gala.
  • The event took place at the Ritz-Carlton, Washington, DC, on October 5, 2023.
  • This is the 20th annual selection of Women Who Mean Business, honoring the Washington, DC region's most influential business women of 2023.
  • The honor and event is produced and hosted by the Washington Business Journal.

BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer

Retrieved on: 
Wednesday, October 4, 2023
Partnership, Therapy, Upstate New York, Survival, Cancer, Patient, TSX, Health, BCT, Hospital

“Cancer is complex.

Key Points: 
  • “Cancer is complex.
  • It takes a village to care for a cancer patient.
  • At NYCBS, our mission is to offer cancer patients access to state-of-the-art treatments close to their homes, families, and support networks at convenient locations across Long Island, New York City, and Upstate New York,” stated Dr. Jeffrey Vacirca, CEO of NYCBS.
  • “Their insights and dedication to excellent patient care will be of utmost importance to us in our upcoming pivotal registration study.”

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer

Retrieved on: 
Tuesday, October 3, 2023
Biologics license application, Communication, Institutional review board, Survival, Immunotherapy, Patient, IRB, TSX, FDA, Therapy, BCT, Safety, Disease, Pharmaceutical industry

Positive completion of the pivotal study, following review by FDA, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in advanced metastatic breast cancer.

Key Points: 
  • Positive completion of the pivotal study, following review by FDA, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in advanced metastatic breast cancer.
  • The study will enroll 177 patients in the Bria-IMT™ combination therapy arm and 177 patients in the treatment of physician’s choice arm.
  • We expect frequent and responsive FDA communication under our Fast Track status during our pivotal Phase 3 study.
  • The successful completion of the pivotal study would allow BriaCell to subsequently submit a Biologics License Application and accelerate the path to commercialization.

SingleStore Announces New Real-Time Generative AI Event, Features and Partnerships

Retrieved on: 
Thursday, September 21, 2023
Data Management, Other Technology, Apps, Applications, Technology, Artificial Intelligence, Cloud, SingleStore, Database, LLM, IBM, Enterprise, Amazon Web Services, Gen, API, Chase Center, Intelligence, CMO, Mapletree Investments, Organization, Google Cloud, Growth, Ecosystem, BCT, AWS, Cryptocurrency, Management, Medical device, Sales, Cognizant

The one-day conference will showcase hands-on sessions on how developers can build and scale compelling enterprise-ready generative AI applications and the agenda will feature topics such as: “Intro to Building Generative AI Applications using LLMs,” “Building an End-to-End Enterprise Generative AI App Using Llama 2 and LangChain,” “How to Build a Real-Time Enterprise AI Application Using Kafka” and much more.

Key Points: 
  • The one-day conference will showcase hands-on sessions on how developers can build and scale compelling enterprise-ready generative AI applications and the agenda will feature topics such as: “Intro to Building Generative AI Applications using LLMs,” “Building an End-to-End Enterprise Generative AI App Using Llama 2 and LangChain,” “How to Build a Real-Time Enterprise AI Application Using Kafka” and much more.
  • “We are very excited about the cutting edge vector capabilities in our database to help power Gen AI use cases,” said Raj Verma, SingleStore CEO.
  • These partners will showcase how they’re innovating with SingleStore and integrating AI capabilities into their systems and products.
  • These partners will showcase how they’re innovating with SingleStore and integrating AI capabilities into their systems and products.

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Retrieved on: 
Friday, September 8, 2023
Probability, University, E pluribus unum, Survival, Merck & Co., Life expectancy, Associate, Trial of the century, Medicine, Terminal, Literature, Kaplan–Meier estimator, Publication, Patient, Breast cancer, JAMA Oncology, TSX, Financial toxicity, Merck, Pembrolizumab, Therapy, BCT, Birth control, Pharmaceutical industry

Median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature)

Key Points: 
  • Median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature)
    PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.
  • “The overall safety profile and survival data in advanced metastatic breast cancer is extremely encouraging in this heavily pre-treated patient population.”
    “We are forging a new path for advanced metastatic breast cancer, a terminal disease with a very limited life expectancy of 6.7 to 9.8 months,” stated Dr. William V. Williams, BriaCell’s President and CEO.
  • The overall survival in advanced breast cancer patients (third line or later) is very limited, 6.7-9.8 months in publications that evaluated similar patients (Cortes J, et al.
  • The survival findings support BriaCell’s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT™ and support using this combination regimen for our upcoming pivotal study in advanced breast cancer.

Fujifilm Introduces FUJINON Duvo™ HZK24-300mm Portable PL Mount Zoom Lens

Retrieved on: 
Thursday, September 7, 2023
IBC, Steadicam, Lens, Fujifilm, Attention, RBF, Distortion, ZEISS, BCT, Camera, Telescopic sight

VALHALLA, N.Y., Sept. 07, 2023 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation, Optical Devices Division (“Fujifilm”) announces the introduction of the FUJINON Duvo™ [1] HZK24-300mm Portable PL Mount Zoom Lens (“Duvo 24-300mm”), a dual format lens supporting two types of large-image sensors [2] , specializing in shallow depth-of-field and beautiful bokeh.

Key Points: 
  • VALHALLA, N.Y., Sept. 07, 2023 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation, Optical Devices Division (“Fujifilm”) announces the introduction of the FUJINON Duvo™ [1] HZK24-300mm Portable PL Mount Zoom Lens (“Duvo 24-300mm”), a dual format lens supporting two types of large-image sensors [2] , specializing in shallow depth-of-field and beautiful bokeh.
  • Complementing Fujifilm’s Duvo™ HZK25-1000mm F2.8-F5.0 PL Mount Cinema Box Lens (“Duvo 25-1000mm”) — Fujifilm’s first Duvo Series lens — Duvo Portable 24-300mm delivers 12.5x zoom, covering 24-300mm, a focal range that is frequently used on set.
  • It enables the recording of lens metadata (focus, zoom, and iris position), as well as of lens distortion and shading corrections.
  • Duvo 24-300mm is currently expected to be available in the U.S. market in the spring of 2024 but will be previewed at IBC 2023 in Amsterdam, Netherlands from September 15 to 18, 2023 along with Fujifilm’s third Duvo Series lens, a wide portable zoom lens covering a focal length of 14-100mm.For more information on the Duvo 24-300mm PL Mount Zoom Lens, please visit https://fujinon.com/duvo .

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

Retrieved on: 
Thursday, August 31, 2023
Cancer, Corporate spin-off, Arrangement, Related, EDGAR, Bangladesh Securities and Exchange Commission, Corporation, National instrument, SEDAR, Computershare, TSX, Toronto Stock Exchange, Letter, Therapy, BCT, News, Security (finance)

BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement.

Key Points: 
  • BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement.
  • Under the terms of the Arrangement, for each BriaCell share held immediately prior to closing, BriaCell Shareholders receive one (1) common share of SpinCo, and one (1) new common share of BriaCell (retiring their old share) having the same terms and characteristics as the existing BriaCell common shares.
  • The Corporation now beneficially owns or controls approximately 31,963,452 SpinCo common shares, representing 2/3rd of the issued and outstanding SpinCo common shares.
  • The Company expects the new BriaCell common shares to begin trading on or about September 5, 2023, under the symbol "BCT".